Figure 8. LncRNA MALAT1 enhanced CAD progression via activating mTOR signaling pathway. (A, B) QRT-PCR results of VCAM-1/ICAM-1 expression in different transcription groups. **P<0.01, compared with NC group. (C, D) Western blot results showed that both sh-MALAT1#1 and miR-15b-5p mimics depressed expression of ERK1/2, phosphorylated mTOR. Both CCCP and miR-15b-5p mimics promoted expression of ATG1 and LC3-II. Nevertheless, both miR-15b-5p inhibitor and pCMV6-MAPK1 suppressed expression of ATG1 and LC3-II. Nevertheless, both miR-15b-5p inhibitor and pCMV6-MAPK1 enhanced expression of MPKA1 and phosphorylated mTOR. MiR-15b-5p inhibitor + sh-MALAT1#1 group, miR-15b-5p mimics + pCMV6-MALAT1 as well as miR-15b-5p mimics + pCMV6-MAPK1 group exhibited similar results of NC group. *P<0.05, **P<0.01, compared with NC group.